Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 29;28(9):1872–1882. doi: 10.1038/s41591-022-01916-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a–c, Correlation between CXCL9 gene expression in pre-treatment tumor biopsies and CD8⁺ T cell tumor infiltrate measured by Immunoscore TCE panel (a) or CD8A gene expression (b,c) in patients in ZUMA-1 (subset 1; n = 19) (a), second-line patients with DLBCL (n = 252) (b) and treatment-naive patients with DLBCL (n = 67) (c). Gene expression was measured by PanCancer Immune panel for a and c and Immuno-Oncology 360 panel for b. d–f, Correlation matrix for myeloid-secreted and/or T cell–produced cytokines and chemokines (horizontal axis) with T cell subset–related genes (vertical axis) in pre-treatment tumor biopsies from ZUMA-1 (d), second-line (e) and treatment-naive patients with DLBCL (f). The scale bar (−1 to 1) represents the R value. The gray ribbons represent the 95% confidence interval of the regression line. Statistical significance of the Spearman coefficient level (two-sided P value as shown) was calculated. CCL, chemokine ligand; CXCL, chemokine C-X-C motif ligand; FoxP3, forkhead box P3; GNLY, granulysin; GZMA, granzyme A; IL, interleukin; IRF1, interferon regulatory factor 1; PD, progressive disease; PR, partial response; SD, stable disease; STAT, signal transducer and activator of transcription; NFRSF14, tumour necrosis factor receptor superfamily member 14.